Not yet reviewed — this article is pending editorial review by Lyrea.

3-MeO-PCPr

3-Methoxy-N-propylphencyclidamine

3-Methoxyphencyclidine propylamino

Psychoactive Class

Dissociative Hallucinogen Stimulant (mild)

Chemical Class

Arylcyclohexylamine

3-MeO-PCPr is a dissociative research chemical of the arylcyclohexylamine class.¹ It is the N-propyl homologue of 3-MeO-PCE and is reported to be slightly less potent than PCP while producing a somewhat less manic experience by comparison. As a relatively obscure research chemical, very limited data exists regarding its safety profile, pharmacology, and long-term effects. Like other arylcyclohexylamines, it may carry a risk of habit formation.²

Dosage & Duration

Dosage

Doses are population estimates that vary widely between individuals.

Threshold~1 mg

Light1-3 mg

Moderate3-8 mg

Strong8-15 mg

Heavy15+ mg

Duration

Onset5-10 minutes

Total1-3 hours

Subjective Effects

Available documentation of 3-MeO-PCPr is minimal and consists mainly of comparative characterization rather than detailed accounts of the experience. It is described as somewhat less potent than PCP, and as producing a less manic quality than related compounds.

Pharmacology

Pharmacodynamics

Published literature places 3-MeO-PCPr among arylcyclohexylamines perceived as ketamine-like dissociatives and believed to act predominantly through NMDA-receptor antagonism. The compound-specific study was analytical, not a clinical pharmacology study, so this is not a complete receptor profile or evidence of human efficacy. [S1][S2]¹³

Pharmacokinetics

The inspected analytical paper and PCP-NPS review reported no compound-specific absorption, bioavailability, distribution, metabolism, elimination, or half-life values for 3-MeO-PCPr; numerical pharmacokinetic fields should remain empty. [S1][S2]¹³

Metabolitesnone documented yet

Interactions

Interactions not written up yet

An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.

Check

TripSit

Tolerance

Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.

Cross Tolerance

Dissociatives (NMDA receptor antagonists)

Harm Potential

Addiction & Dependence

Psychological

Moderate

Classified as habit-forming, though specific addiction potential has not been formally characterized.

History & Culture

Online documentation

A surviving Bluelight thread dated 2 October 2011 contains a self-report and discussion of 3-MeO-PCPr. This establishes online discussion by that date, not first synthesis or first use.⁴

Legality

International

As of 23 August 2026, 3-MeO-PCPr (N-propyl-1-(3-methoxyphenyl)cyclohexan-1-amine) is not named or chemically designated in the current complete INCB Yellow, Green or Red Lists. The Green List instead places PCE (N-ethyl-1-phenylcyclohexylamine) and PHP/PCPy (1-(1-phenylcyclohexyl)pyrrolidine) in Schedule I and separately places 3-methoxyphencyclidine (1-(1-(3-methoxyphenyl)cyclohexyl)piperidine) in Schedule II. Those exact designations do not cover the target, which the analytical literature identifies as the 3-methoxyphenyl N-propyl compound rather than the N-ethyl, pyrrolidine or piperidine compounds. The Green List extends control to salts and applicable stereoisomers of listed substances, not to otherwise distinct N-alkyl analogues. INCB's March 2026 notice adds only MDMB-FUBINACA to Schedule II, with effect from 25 November 2026, and does not name 3-MeO-PCPr. The current INCB materials therefore establish no scheduling of 3-MeO-PCPr under the 1961, 1971 or 1988 Conventions.

By Country

ArgentinaIllegal (analog/blanket ban)Estupefaciente

Decreto 560/2019, artículo 2 y Anexo II, Grupo 2⁵⁶

Argentina controls 3-MeO-PCPr through the arylcyclohexylamine chemical group in Annex II of Decree 560/2019 rather than by individual name. Group 2 permits N-alkyl substituents through C8 and methoxy substitution anywhere on the aromatic ring, matching the compound's N-propyl and 3-methoxy structure; article 2 treats substances within the Annex II groups as estupefacientes.

AustriaIllegal (analog/blanket ban)Anlage II group 8

Neue-Psychoaktive-Substanzen-Verordnung, Anlage II group 8; Neue-Psychoaktive-Substanzen-Gesetz, section 4⁹¹⁰

Austria's NPS regulation covers every compound derivable from the arylcyclohexylamine, arylcyclohexyl-pyrrolidine, or arylcyclohexyl-piperidine core structures. The NPS Act penalizes profit-motivated manufacture, import, export, transfer, or procurement undertaken with the intent that the substance be used for psychoactive effect.

GermanyIllegal (analog/blanket ban)Stoffgruppe 6

Neue-psychoaktive-Stoffe-Gesetz, Anlage 1 no. 6¹²

Germany controls 3-MeO-PCPr through the NpSG group for arylcyclohexyl(methyl)amine-derived compounds rather than by its individual name. Group 6 permits N-alkyl groups through C6, a phenyl ring bearing alkoxy substitution through C6, and a molecular mass up to 500 u, which encompasses the N-propyl and 3-methoxy structure.

New ZealandIllegal (analog/blanket ban)Class C controlled drug

Misuse of Drugs Act 1975, Schedule 3, Part 7 (Phencyclidine analogues)^151617118

As of 23 August 2026, 3-MeO-PCPr is not individually named but falls within Schedule 3 Part 7's generic description of phencyclidine analogues. The statutory category covers a 1-alkylamino-1-arylcyclohexane whose alkylamino radical has up to 6 carbon atoms, whose aryl radical is phenyl, and whose aryl radical may carry qualifying alkoxy substituents. The peer-reviewed analytical study identifies 3-MeO-PCPr as N-propyl-1-(3-methoxyphenyl)cyclohexan-1-amine: it therefore has a three-carbon propylamino radical and a phenyl radical carrying one one-carbon methoxy radical at the same cyclohexane carbon. Those features satisfy the generic description directly, without relying on the separate and less determinate test of whether an unlisted structure is substantially similar to another controlled drug. Because the description appears in Schedule 3, the applicable designation is Class C controlled drug.

RussiaIllegal (analog/blanket ban)Список I

Government Decree No. 681 of 30 June 1998, List I and note 6²⁰

Russia controls 3-MeO-PCPr as a derivative of the expressly listed 1-phenylcyclohexylamine rather than by individual name. Its structure results from formal substitution of an aromatic hydrogen by methoxy and an amine hydrogen by propyl, within note 6's derivative definition and carbon-count limit; List I circulation is prohibited.

South AfricaIllegal (analog/blanket ban)Schedule 2 Part III

Drugs and Drug Trafficking Act 140 of 1992, Schedule 2 Part III²³

Schedule 2 Part III lists phencyclidine and named congeners and extends the Part to all homologues, defined as chemically related substances incorporating a similar structural fragment or exhibiting similar pharmacodynamic properties. The N-propyl and 3-methoxy phencyclidine-family structure of 3-MeO-PCPr falls within that homologue clause, and sections 4 and 5 prohibit unauthorized use, possession, and dealing.

SwitzerlandIllegal (analog/blanket ban)Verzeichnis e

Betäubungsmittelverzeichnisverordnung, Anhang 6, Verzeichnis e, no. 291²⁵

Switzerland covers 3-MeO-PCPr through the generic phenylcyclohexylamine entry in Schedule e rather than by individual name. The current ordinance includes N-alkyl substitution to any extent and aromatic alkoxy substitution to any extent; industrial and scientific use is excepted, but private use is expressly not excepted.

AustraliaIllegal (analog/blanket ban)Controlled-drug analogue

Criminal Code Act 1995, sections 301.1, 301.4 and 301.9; Criminal Code Regulations 2019, Schedules 1 and 2⁷⁸

At Commonwealth level, 3-MeO-PCPr is covered as a controlled-drug and border-controlled-drug analogue of listed phencyclidine. Section 301.9 includes structural modifications substituting alkoxy for hydrogen, N-alkyl substitution, chemical derivatives, and substances substantially similar in chemical structure; the regulations list phencyclidine as both a controlled drug and a border controlled drug.

CanadaIllegal (analog/blanket ban)Schedule I analogue

Controlled Drugs and Substances Act, Schedule I, item 14¹¹

Canada's Schedule I phencyclidine entry expressly includes its derivatives and analogues, and the Act defines an analogue as a substance with a substantially similar chemical structure. 3-MeO-PCPr is controlled through that generic entry rather than by an individual short-name listing, making unauthorized possession an offence under section 4.

IrelandIllegal (analog/blanket ban)Psychoactive substance

Criminal Justice (Psychoactive Substances) Act 2010, sections 1 and 3¹³¹⁴

Ireland's capacity-based definition covers a substance that stimulates or depresses the central nervous system and causes specified changes in perception, awareness, mood, thinking, behaviour, or motor function. The Act criminalizes knowing or reckless sale, import, or export for human consumption; it does not create a general personal-possession offence.

PolandIllegal (analog/blanket ban)VII-NPS

Rozporządzenie Ministra Zdrowia z dnia 17 sierpnia 2018 r., załącznik nr 3 część 8¹⁹

Poland's NPS schedule controls arylcyclohexylamine derivatives up to 500 u through group VII-NPS. The group permits an alkoxy substituent through C6 on the aromatic ring and an N-alkyl substituent through C6, placing the N-propyl and 3-methoxy structure of 3-MeO-PCPr within the group without an individual listing.

SingaporeIllegal (analog/blanket ban)Psychoactive substance

Misuse of Drugs Act 1973, Part 2A²¹²²

Singapore's capacity-based framework applies to substances capable of producing a psychoactive effect even when they are not scheduled as controlled drugs. Part 2A criminalizes trafficking, manufacture, import, export, possession, and consumption, subject to the statutory exclusion framework for legitimate-use substances.

South KoreaIllegal (analog/blanket ban)Category A psychotropic

Enforcement Decree of the Narcotics Control Act, Annex 3, item 21²⁴

South Korea's Annex 3 controls phencyclidine analogues through a generic structural definition. The definition permits N-alkylamino groups and substituted phenyl rings, encompassing the N-propylamino and 3-methoxyphenyl features of 3-MeO-PCPr without an individual short-name listing.

United KingdomIllegal (analog/blanket ban)Class B

Misuse of Drugs Act 1971, Schedule 2 Part II paragraph 1(d), as inserted by S.I. 2013/239²⁶

The United Kingdom's Class B generic definition covers compounds derived from 1-phenylcyclohexylamine by N-alkyl substitution and by alkoxy substitution on the phenyl ring. The N-propyl and 3-methoxy substitutions of 3-MeO-PCPr fall directly within those two limbs of the definition.

References

Source Pages

Citations

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the 3-MeO-PCPr article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.